Biohaven Pharmaceutical Holding Market Cap 2016-2022 | BHVN
Biohaven Pharmaceutical Holding market cap history and chart from 2016 to 2022. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Biohaven Pharmaceutical Holding market cap as of August 10, 2022 is $10.53B.
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Biomedical and Genetics | $10.535B | $0.463B |
| Biohaven Pharmaceutical is a commercial-stage biotechnology company focused on developing, and commercializing products, primarily in the fields of central nervous system diseases, including neurological and rare disorders. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bristol Myers Squibb (BMY) | United States | $160.059B | 9.71 |
| GSK (GSK) | United Kingdom | $81.408B | 9.78 |
| Bio-Rad Laboratories (BIO.B) | United States | $15.412B | 34.05 |
| QIAGEN (QGEN) | Netherlands | $11.018B | 18.45 |
| Ginkgo Bioworks Holdings (DNA) | United States | $5.561B | 0.00 |
| Arcus Biosciences (RCUS) | United States | $1.821B | 35.53 |
| Myovant Sciences (MYOV) | United Kingdom | $1.600B | 0.00 |
| Emergent Biosolutions (EBS) | United States | $1.482B | 8.59 |
| Zymeworks (ZYME) | Canada | $0.390B | 0.00 |
| Enzo Biochem (ENZ) | United States | $0.120B | 0.00 |
| Gelesis Holdings (GLS) | United States | $0.104B | 0.00 |
| SQZ Biotechnologies (SQZ) | United States | $0.097B | 0.00 |
| Ambrx Biopharma (AMAM) | United States | $0.089B | 0.00 |
| ADC Therapeutics SA (ADCT) | Switzerland | $0.000B | 0.00 |
